Healthcare / BiotechnologyNasdaqCM
$0.63
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-21.2M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
445.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-29.6M · FCF $-21.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-29.6M | $-29.6M | $-13.7M | $-34.4M | $-7.8M | $-35.8M | $-27.5M | $-37.0M |
| EBITDA | — | — | — | $-38.0M | $-14.1M | — | — | — |
| EPS | -1.97 | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-21.2M | $-21.2M | $-21.2M | $-25.8M | $-11.8M | $-32.0M | $-33.1M | $-31.8M |
| Returns | ||||||||
| ROE | 445.1% | 445.1% | -95.1% | -421.2% | 11.0% | 56.0% | -29.0% | 36.0% |
| Growth & Yield | ||||||||
| EPS Growth | -61.5% | -61.5% | 84.1% | 93.1% | -6477.5% | — | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.